RE:RE:RE:RE:RE:Many new job postings One thought is maybe TH will get an invite to speak at the JP Morgan Healthcare conference this year if this fellow is trying to win their business. But it is hard to see JPM giving them a loan to get the NASH trial started unless it is an accounts receivable backed loan as I suggested earlier. I cannot see them doing any normal commercial loan with JPM to finance clinical research - that just does not happen. Also, it seems to me to be odd that a JPM banker would be trying to curry favor with TH in this manner.
qwerty22 wrote: Anybody got any more thoughts on this? It doesn't get more scrappier than this scrap of info but it's intriguing.
jfm1330 wrote: On Linkedin, one of the person giving a thumb up to the poste about hiring at Thera is this guy
https://www.jpmorgan.com/commercial-banking/industries/life-sciences/chris-barrow
jfm1330 wrote: Thera is not running clinical trial in oncology by themselves. This is outsourced to a contract research organisation called PPD and the principal investigator, Dr. Funda Meric-Burnstam works for M.D. Anderson cancer center. Thera already has the personal needed to coordinate everything with the CRO. If they move to multiple phase II at the same time in the second half of 2022, they will hire more people, that's sure. But for now, I think they have enough people to handle the job on that front.
https://www.ppd.com/
https://clinicaltrials.gov/ct2/show/NCT04706962?term=theratechnologies&draw=2&rank=1
SPCEO1 wrote: The lack of clinical jobs being posted is something to think about. Should we assume a lot of partnerships are in TH's future where that work will be mostly done outside of TH and therefore there is no need for big staff additions there? Or, will we see a wave of scientific positions being filled after/if the phase 1a produces promising results?